Key Events This Week
23 Mar: Valuation shifts to fair amid sector comparisons
27 Mar: Technical momentum shifts amid mixed market signals
27 Mar: Week closes at Rs.765.45 (+5.32%) outperforming Sensex
May 07
BSE+NSE Vol: 30.97 k

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
The Sensex advanced 1.79% on 15 Apr 2026, yet Windlas Biotech Ltd outpaced the broader market with a 7.09% gain, touching an intraday high of Rs 875.45. This 5.15-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.
Read full news article
Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 12 April 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
23 Mar: Valuation shifts to fair amid sector comparisons
27 Mar: Technical momentum shifts amid mixed market signals
27 Mar: Week closes at Rs.765.45 (+5.32%) outperforming Sensex

Windlas Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from Hold to Sell by MarketsMOJO on 4 February 2026, the stock’s price action and technical indicators suggest a cautiously evolving outlook for investors.
Read full news article
Windlas Biotech Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating, reflecting evolving market perceptions amid a challenging sector backdrop. Despite a modest day gain of 1.90%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more tempered price attractiveness compared to its historical averages and peer group benchmarks.
Read full news article
16 Mar: Stock hits 52-week low at Rs.699.35 amid continued downtrend
17 Mar: Price rebounds sharply by 2.21% to Rs.724.15
18 Mar: Further gains of 1.12% to Rs.732.25
19 Mar: Sharp decline of 1.99% to Rs.717.65 on heavy market sell-off
20 Mar: Recovery with 1.27% gain to close at Rs.726.80
No Upcoming Board Meetings
Windlas Biotech Ltd has declared 116% dividend, ex-date: 21 Jul 25
No Splits history available
No Bonus history available
No Rights history available